Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (ESPR) is a biopharmaceutical innovator focused on developing oral non-statin therapies for cardiovascular patients with elevated LDL cholesterol. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.
Access ESPR’s latest press releases covering FDA approvals, clinical trial results, and partnership announcements with global pharmaceutical leaders. Our curated collection includes earnings reports, research breakthroughs, and market expansion updates—all essential for understanding the company’s position in cholesterol management innovation.
Discover updates on bempedoic acid developments, international licensing agreements, and R&D pipeline progress. This resource serves as your primary source for tracking ESPR’s mission to address unmet needs in cardiovascular care through targeted therapeutic solutions.
Bookmark this page for streamlined access to verified Esperion Therapeutics announcements. Check regularly for new insights into one of biopharma’s most focused approaches to LDL-C reduction without statin-related limitations.
Esperion (NASDAQ: ESPR) presented two post hoc analyses from CLEAR Outcomes at AHA Scientific Sessions 2025 (Nov 7-10). In ~8,200 patients receiving no background lipid‑lowering therapy, bempedoic acid monotherapy lowered LDL‑C by 20.6% at 6 months and reduced MACE‑4 by 14% versus placebo. A separate exploratory analysis reported a 42% lower risk of venous thromboembolism (VTE) with bempedoic acid (106 VTE events over 40.6 months); DVT risk -44% and PE risk -39% versus placebo. Safety profiles were reported as similar for total and serious adverse events; labeling warns about hyperuricemia and tendon rupture.
Esperion (NASDAQ: ESPR) announced that on November 4, 2025 it granted 77,650 restricted stock units (RSUs) to 23 new employees under its 2017 Inducement Equity Incentive Plan pursuant to NASDAQ Rule 5635(c)(4).
The RSUs vest 25% on the one-year anniversary of each recipient’s vesting commencement date and the remaining 75% in twelve equal quarterly installments thereafter, subject to continued employment. The awards are governed by the 2017 Inducement Equity Incentive Plan and individual RSU agreements.
Esperion is a commercial-stage biopharmaceutical company commercializing FDA-approved oral, once-daily non-statin medicines for patients with elevated LDL-C and references the nearly 14,000-patient CLEAR Cardiovascular Outcomes Trial.
Esperion (NASDAQ: ESPR) reported Q3 2025 total revenue of $87.3M, up 69% year‑over‑year, driven by U.S. prescription volume and expanded payer coverage. U.S. net product revenue was $40.7M, up 31% Y/Y. The company announced a settlement with ANDA filer Dr. Reddy’s and three other filers preventing generic marketing of NEXLETOL and NEXLIZET prior to April 2040. Bempedoic acid received a Class I, Level A recommendation in the 2025 ESC/EAS guidelines. Partner Otsuka received Japanese approval and favorable preliminary pricing for NEXLETOL, which will trigger material milestone payments upon final pricing.
Esperion ended Q3 with $92.4M cash, reported a Q3 net loss of $31.3M, reiterated 2025 operating expense guidance of $215M–$235M, and expects sustainable profitability beginning Q1 2026.
Esperion (NASDAQ: ESPR) announced the appointment of John Harlow as Chief Commercial Officer, effective November 17, 2025. He will report to President and CEO Sheldon Koenig and join the executive leadership team.
Harlow joins from Melinta Therapeutics, where he served as CCO and led a commercial platform and team of ~80 employees, helping drive roughly 85% revenue growth in 2024 vs 2020. He has prior commercial leadership roles at Baudax Bio, Recro Pharma, Endo, Shionogi USA, Pfizer, Alpharma, and Novartis, plus an MBA in Pharmaceutical Management and Marketing.
Esperion cited Harlow’s experience as central to expanding U.S. adoption and the global footprint for its therapies NEXLETOL and NEXLIZET.
Esperion (NASDAQ: ESPR) will present at the Jefferies Global Healthcare Conference – London on November 18, 2025 at 8:00 a.m. GMT (3:00 a.m. ET).
The presentation will be webcast live and accessible via the company investor website. A replay will be available approximately two hours after the call and will be archived on the company website for approximately 90 days. Esperion is a commercial-stage biopharmaceutical company developing oral, once-daily, non-statin medicines for patients with elevated LDL-C and is advancing next-generation ACLY inhibitor programs supported by prior CLEAR outcomes research.
Esperion (NASDAQ: ESPR) will host a virtual Key Opinion Leader event on Tuesday, November 11, 2025 at 2:00 p.m. ET to discuss clinical and real-world challenges of statin intolerance and impacts on patient outcomes. The event is led by LeAnne Bloedon, VP, Head of Clinical Development, and features experts including Fatima Rodriguez, MD, MPH, and Dharmesh S. Patel, MD.
The company highlighted that nearly 20% of patients discontinue statins within one year and emphasized dialogue on strategies—including bempedoic acid therapies. A live audio webcast and replay (available ~2 hours after the call) will be posted on the investor section of the Esperion website and archived for ~90 days.
Esperion (NASDAQ: ESPR) announced that two analyses from the CLEAR Outcomes trial were accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, November 7-10, 2025.
An oral presentation titled “Bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events: a secondary analysis of the CLEAR Outcomes trial” is scheduled for November 9, 2025, 9:45–11:00 AM CST, presented by Carolina Pires Zingano, MD of Cleveland Clinic. A poster, “Effects of Bempedoic Acid on Venous Thromboembolism: a Post-Hoc Analysis of the CLEAR Outcomes trial”, will appear in the moderated digital poster session VM.MDP.07 on November 9, 2025, 11:50 AM–1:05 PM CST, presented by Bernardo Frison Spiazzi, MD of Cleveland Clinic.
Company leadership highlighted that CLEAR Outcomes continues to yield clinically relevant insights on statin intolerance and treatment options for patients with elevated LDL-C.
Esperion (NASDAQ: ESPR) will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025.
Management will host a live webcast at 8:00 a.m. ET to discuss results and business updates; a replay will be available about two hours after the call and archived on the company website for ~90 days.
Esperion is a commercial-stage biopharmaceutical company marketing the only FDA-approved oral, once-daily non-statin therapies for patients with elevated LDL-C, supported by the ~14,000-patient CLEAR cardiovascular outcomes trial. The company is advancing next-generation ATP citrate lyase inhibitor (ACLYi) programs and pursuing international partnerships and commercial expansion.
Esperion (NASDAQ: ESPR) nominated ESP-2001, a highly-specific allosteric ACLY inhibitor, as its preclinical development candidate for primary sclerosing cholangitis (PSC) on October 16, 2025. The company will begin IND-enabling studies with a goal to file an IND with the FDA in 2026 to start first-in-human trials. Preclinical models reportedly showed consistent reductions in markers of liver and bile duct injury, inflammation, and fibrosis. Esperion retains exclusive global development and commercialization rights and cites an estimated diagnosed PSC prevalence of ~76,000 in the U.S. and Europe and a potential market opportunity of over $1 billion annually. ESP-2001 may be eligible for Orphan Drug, Fast Track, and PRIME designations.
Esperion (Nasdaq: ESPR) priced an underwritten public offering of 30,000,000 common shares at $2.50 per share, with a 30-day underwriter option for up to 4,500,000 additional shares. Gross proceeds before fees are expected to be approximately $75.0 million, excluding any exercise of the option.
The offering is expected to close on or about October 9, 2025, subject to customary closing conditions, and is being sold pursuant to an effective shelf registration declared effective by the SEC on April 29, 2025. Piper Sandler and Cantor Fitzgerald are joint book‑running managers.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
